Use of corticosteroids in the sepsis syndrome: What do we know now?
Steven P. LaRosa, MD
Director, Ocean State Clinical Coordinating Center; Attending Physician, Division of Infectious Disease, Rhode Island Hospital; Assistant Professor of Medicine, Brown Medical School, Providence, RI
Address: Steven LaRosa, MD, Rhode Island Hospital, Gerry House 113, 593 Eddy Street, Providence, RI 02903; e-mail firstname.lastname@example.org
ABSTRACTSeveral lines of evidence support the use of corticosteroids as adjunctive therapy for sepsis. In human trials, high-dose, short-course corticosteroid therapy for sepsis has not shown benefit, but prolonged use of low doses has shown benefit in patients with vasopressor-dependent septic shock. The Corticosteroid Therapy of Septic Shock (CORTICUS) trial is addressing the remaining questions regarding the ideal target population for corticosteroid therapy, as well as the best definition of relative adrenal insufficiency in the critically ill.